ATE530530T1 - Diaminopyrimidincarbonsäureamidderivat - Google Patents
DiaminopyrimidincarbonsäureamidderivatInfo
- Publication number
- ATE530530T1 ATE530530T1 AT03761820T AT03761820T ATE530530T1 AT E530530 T1 ATE530530 T1 AT E530530T1 AT 03761820 T AT03761820 T AT 03761820T AT 03761820 T AT03761820 T AT 03761820T AT E530530 T1 ATE530530 T1 AT E530530T1
- Authority
- AT
- Austria
- Prior art keywords
- diaminopyrimidine
- acid amide
- carbonic acid
- amide derivative
- substituted
- Prior art date
Links
- -1 DIAMINOPYRIMIDINE CARBONIC ACID AMIDE DERIVATIVE Chemical class 0.000 title abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002190959 | 2002-06-28 | ||
| PCT/JP2003/008129 WO2004002964A1 (ja) | 2002-06-28 | 2003-06-26 | ジアミノピリミジンカルボキサミド誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE530530T1 true ATE530530T1 (de) | 2011-11-15 |
Family
ID=29996904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03761820T ATE530530T1 (de) | 2002-06-28 | 2003-06-26 | Diaminopyrimidincarbonsäureamidderivat |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7449456B2 (de) |
| EP (1) | EP1518855B1 (de) |
| JP (2) | JP4529685B2 (de) |
| CN (1) | CN1665789A (de) |
| AT (1) | ATE530530T1 (de) |
| AU (1) | AU2003244098A1 (de) |
| CA (1) | CA2490888C (de) |
| ES (1) | ES2373226T3 (de) |
| MX (1) | MXPA04012855A (de) |
| WO (1) | WO2004002964A1 (de) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| DE10223662A1 (de) | 2002-05-28 | 2003-12-11 | Mitsubishi Polyester Film Gmbh | Transparente Polyesterfolie mit verbesserter Wasserdampfbarriere, Verfahren zu ihrer Herstellung und ihre Verwendung |
| ES2373226T3 (es) * | 2002-06-28 | 2012-02-01 | Astellas Pharma Inc. | Derivado de diaminopirimidincarboxamida. |
| IL166241A0 (en) | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| US20040185429A1 (en) * | 2002-12-09 | 2004-09-23 | Judith Kelleher-Andersson | Method for discovering neurogenic agents |
| CL2004000303A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| ES2421139T3 (es) * | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| ATE542801T1 (de) * | 2003-08-15 | 2012-02-15 | Novartis Ag | Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine |
| GB2420559B (en) * | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| ATE540035T1 (de) | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| JP2008540436A (ja) * | 2005-05-03 | 2008-11-20 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋキナーゼインヒビターおよびそれらの使用 |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| EA015890B1 (ru) * | 2005-06-14 | 2011-12-30 | Тайджен Байотекнолоджи Ко. Лтд. | Производные пиримидина |
| US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
| US7671058B2 (en) | 2006-06-21 | 2010-03-02 | Institute Of Medicinal Molecular Design, Inc. | N-(3,4-disubstituted phenyl) salicylamide derivatives |
| WO2008009458A1 (en) * | 2006-07-21 | 2008-01-24 | Novartis Ag | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
| MX2009004426A (es) | 2006-10-23 | 2009-08-12 | Cephalon Inc | Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. |
| EA019941B1 (ru) | 2006-12-08 | 2014-07-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| DK2146779T3 (en) | 2007-04-18 | 2016-11-28 | Pfizer Prod Inc | Sulfonylamid derivatives to treat abnormal cell growth. |
| KR101294731B1 (ko) * | 2007-06-04 | 2013-08-16 | 삼성디스플레이 주식회사 | 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법 |
| CN101903357A (zh) * | 2007-07-17 | 2010-12-01 | 里格尔药品股份有限公司 | 作为pkc抑制剂的环状胺取代的嘧啶二胺 |
| WO2009119528A1 (ja) * | 2008-03-24 | 2009-10-01 | 武田薬品工業株式会社 | 複素環化合物 |
| CA2723205C (en) * | 2008-04-16 | 2017-03-14 | Portola Pharmaceuticals, Inc. | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors |
| US8063058B2 (en) | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
| KR20100132550A (ko) * | 2008-04-16 | 2010-12-17 | 포톨라 파마슈티컬스, 인코포레이티드 | ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드 |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| AU2009251863B2 (en) * | 2008-04-16 | 2014-09-25 | Alexion Pharmaceuticals, Inc. | 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors |
| AU2008355098B2 (en) | 2008-04-21 | 2012-11-15 | Gpcr Therapeutics, Inc | Heterocyclic compounds |
| KR101361027B1 (ko) * | 2008-11-28 | 2014-02-11 | 코와 가부시키가이샤 | 피리딘-3-카르복시아미드 유도체 |
| FR2941698B1 (fr) | 2009-01-30 | 2012-07-27 | France Etat | Procede d'identification de microorganisme, sans a priori et kit d'identification |
| WO2010129802A1 (en) * | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
| MX2011011875A (es) | 2009-05-08 | 2011-12-08 | Astellas Pharma Inc | Compuesto de carboxamida heterociclica diamino. |
| US8410126B2 (en) * | 2009-05-29 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Pyrimidine inhibitors of PKTK2 |
| WO2011065800A2 (ko) * | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| EP2560488B1 (de) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Bestimmte aminopyrimidine und aminotriazine, zusammensetzungen daraus und verfahren zu ihrer verwendung |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| JP5951600B2 (ja) | 2010-05-21 | 2016-07-13 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | キナーゼ調節のための、化合物、組成物および方法 |
| AU2015201030B2 (en) * | 2011-04-22 | 2016-09-29 | Signal Pharmaceuticals, Llc | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
| TWI548621B (zh) * | 2011-04-22 | 2016-09-11 | 標誌製藥公司 | 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法 |
| AU2016244228B2 (en) * | 2011-04-22 | 2019-02-21 | Signal Pharmaceuticals, Llc | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
| WO2013054351A1 (en) * | 2011-08-08 | 2013-04-18 | Cadila Healthcare Limited | Heterocyclic compounds |
| PE20141371A1 (es) | 2011-08-29 | 2014-10-13 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos |
| WO2013078468A1 (en) * | 2011-11-23 | 2013-05-30 | Portola Pharmaceuticals, Inc. | Selective kinase inhibitors |
| EP2782579B1 (de) | 2011-11-23 | 2019-01-02 | Portola Pharmaceuticals, Inc. | Pyrazinkinaseinhibitoren |
| EP2802579B1 (de) | 2012-01-13 | 2016-04-13 | Bristol-Myers Squibb Company | Thiazolyl-oder thiadiazolyl-substituierte als kinaseinhibitor geeignete pyridylverbindungen |
| WO2013106614A1 (en) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| ES2686500T3 (es) | 2012-01-13 | 2018-10-18 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con heterocíclicos, útiles como inhibidores de cinasas |
| JP2015517574A (ja) * | 2012-05-22 | 2015-06-22 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | がん治療のためのピリミジン化合物 |
| EP2711364A1 (de) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl oder benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidine verwendbar für die Behandlung von Krebs |
| EP2711365A1 (de) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidine verwendbar für die Behandlung von Krebs |
| MX2015004801A (es) * | 2012-10-19 | 2015-08-14 | Hoffmann La Roche | Inhibidores de la syk. |
| AU2013341200A1 (en) | 2012-11-08 | 2015-07-02 | Bristol-Myers Squibb Company | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| CA2890935A1 (en) * | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha. |
| CN104781251B (zh) | 2012-11-08 | 2016-12-14 | 百时美施贵宝公司 | 可作为激酶调节剂的经双环杂环取代的吡啶基化合物 |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| WO2014182928A2 (en) | 2013-05-08 | 2014-11-13 | Board Of Regents, The University Of Texas System | Stat6 inhibitors |
| US10329270B2 (en) * | 2013-10-21 | 2019-06-25 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
| AU2014360446A1 (en) | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
| TW201609693A (zh) | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
| NZ715903A (en) * | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
| US10106507B2 (en) * | 2014-08-03 | 2018-10-23 | H. Lee Moffitt Cancer Center and Research Insitute, Inc. | Potent dual BRD4-kinase inhibitors as cancer therapeutics |
| US9513297B2 (en) | 2014-12-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-Jun N-terminal kinase in skin |
| EP3712134B1 (de) | 2014-12-16 | 2023-11-29 | Signal Pharmaceuticals, LLC | Salze von 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidin-5-carboxamid |
| EP3250557B1 (de) | 2015-01-29 | 2024-11-20 | Signal Pharmaceuticals, LLC | Isotopologe von 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidin-5-carboxamid |
| WO2016196385A1 (en) | 2015-05-29 | 2016-12-08 | Portola Pharmaceuticals, Inc. | Cerdulatinib for the treatment of b-cell malignancies |
| CN107849039B (zh) | 2015-06-24 | 2020-07-03 | 百时美施贵宝公司 | 经杂芳基取代的氨基吡啶化合物 |
| EP3313844B1 (de) | 2015-06-24 | 2020-08-26 | Bristol-Myers Squibb Company | Heteroarylsubstituierte aminpyridinverbindungen |
| TW201713655A (zh) | 2015-06-24 | 2017-04-16 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| EP3325432B1 (de) | 2015-07-24 | 2020-09-02 | Celgene Corporation | Verfahren zur synthese von (1r, 2r, 5r)-5-amino-2-methylcyclohexanolhydrochlorid und nützliche zwischenprodukte darin |
| ES2913119T3 (es) | 2015-08-12 | 2022-05-31 | Portola Pharm Inc | Cerdulatinib para tratar mieloma |
| WO2017066428A1 (en) | 2015-10-13 | 2017-04-20 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Brd4-kinase inhibitors as cancer therapeutics |
| EP3383396B1 (de) | 2015-12-04 | 2023-07-12 | Alexion Pharmaceuticals, Inc. | Cerdulatinib und venetoclax zur behandlung von non-hodgkin's lymphom |
| CN106222177B (zh) * | 2016-08-13 | 2018-06-26 | 江苏集萃药康生物科技有限公司 | 一种靶向人STAT6的CRISPR-Cas9系统及其用于治疗过敏性疾病的应用 |
| CA3062602A1 (en) | 2017-05-11 | 2018-11-15 | Bristol-Myers Squibb Company | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
| BR112020013976A2 (pt) | 2018-01-09 | 2020-12-08 | Dermavant Sciences GmbH | Composições farmacêuticas para pele tópicas que contêm cerdulatinibe e usos das mesmas |
| US10851087B2 (en) | 2018-05-04 | 2020-12-01 | Portola Pharmaceuticals, Inc. | Synthesis of cerdulatinib |
| WO2019213606A2 (en) | 2018-05-04 | 2019-11-07 | Portola Pharmaceuticals, Inc. | Solid forms of cerdulatinib |
| JP7620611B2 (ja) | 2019-07-18 | 2025-01-23 | ブリストル－マイヤーズ スクイブ カンパニー | ＩＲＡＫ４阻害剤として有用なピラゾロ［３，４－ｄ］ピロロ［１，２－ｂ］ピリダジニル化合物 |
| WO2021011724A1 (en) | 2019-07-18 | 2021-01-21 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as irak4 inhibitors |
| EP4010317B1 (de) | 2019-08-06 | 2024-06-19 | Bristol-Myers Squibb Company | Bicyclischen heterozyklischen verbindungen verwendbar als irak4 hemmer |
| CN114206874B (zh) | 2019-08-13 | 2024-08-02 | 百时美施贵宝公司 | 可用作irak4抑制剂的双环杂芳基化合物 |
| WO2021158495A1 (en) | 2020-02-03 | 2021-08-12 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors |
| EP4100408B1 (de) | 2020-02-03 | 2024-02-28 | Bristol-Myers Squibb Company | Tricyclische heteroarylverbindungen zur verwendung als irak4-inhibitoren |
| TWI912419B (zh) * | 2020-12-02 | 2026-01-21 | 大陸商深圳微芯生物科技股份有限公司 | 羥肟酸酯化合物、其製備方法及其應用 |
| WO2022188735A1 (en) * | 2021-03-08 | 2022-09-15 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as hpk1 inhibitors |
| TW202304434A (zh) * | 2021-04-08 | 2023-02-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種高活性的ｈｐｋ１激酶抑制劑 |
| EP4401735A4 (de) * | 2021-09-16 | 2025-07-16 | Lomond Therapeutics Inc | Verbindungen mit n-arylpyrimidin-2-amin-derivaten als therapeutische mittel |
| TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ｃｋ１２抑制劑 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2023236945A1 (zh) * | 2022-06-07 | 2023-12-14 | 广州费米子科技有限责任公司 | 哒嗪-3-甲酰胺化合物作为tyk2抑制剂 |
| AU2025221563A1 (en) * | 2024-02-14 | 2026-07-09 | Almirall, S.A. | Stat6 inhibitors and methods of use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE401312T1 (de) * | 1997-12-15 | 2008-08-15 | Astellas Pharma Inc | Pyrimidin-5-carboxamid-derivate |
| ATE245641T1 (de) * | 1998-02-17 | 2003-08-15 | Tularik Inc | Antivirale pyrimidinderivate |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| ES2373226T3 (es) * | 2002-06-28 | 2012-02-01 | Astellas Pharma Inc. | Derivado de diaminopirimidincarboxamida. |
-
2003
- 2003-06-26 ES ES03761820T patent/ES2373226T3/es not_active Expired - Lifetime
- 2003-06-26 MX MXPA04012855A patent/MXPA04012855A/es not_active Application Discontinuation
- 2003-06-26 JP JP2004517299A patent/JP4529685B2/ja not_active Expired - Lifetime
- 2003-06-26 US US10/518,043 patent/US7449456B2/en not_active Expired - Lifetime
- 2003-06-26 AT AT03761820T patent/ATE530530T1/de not_active IP Right Cessation
- 2003-06-26 CN CN038150719A patent/CN1665789A/zh active Pending
- 2003-06-26 AU AU2003244098A patent/AU2003244098A1/en not_active Abandoned
- 2003-06-26 CA CA2490888A patent/CA2490888C/en not_active Expired - Lifetime
- 2003-06-26 WO PCT/JP2003/008129 patent/WO2004002964A1/ja not_active Ceased
- 2003-06-26 EP EP03761820A patent/EP1518855B1/de not_active Expired - Lifetime
-
2008
- 2008-09-22 US US12/235,189 patent/US8012959B2/en not_active Expired - Lifetime
-
2010
- 2010-03-15 JP JP2010057853A patent/JP5104893B2/ja not_active Expired - Lifetime
-
2011
- 2011-06-28 US US13/171,411 patent/US20110294749A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004002964A1 (ja) | 2004-01-08 |
| AU2003244098A1 (en) | 2004-01-19 |
| JP2010174027A (ja) | 2010-08-12 |
| US20050272753A1 (en) | 2005-12-08 |
| CN1665789A (zh) | 2005-09-07 |
| JP4529685B2 (ja) | 2010-08-25 |
| ES2373226T3 (es) | 2012-02-01 |
| EP1518855A4 (de) | 2007-03-14 |
| MXPA04012855A (es) | 2005-04-19 |
| EP1518855B1 (de) | 2011-10-26 |
| JPWO2004002964A1 (ja) | 2005-10-27 |
| EP1518855A1 (de) | 2005-03-30 |
| US20110294749A1 (en) | 2011-12-01 |
| US8012959B2 (en) | 2011-09-06 |
| JP5104893B2 (ja) | 2012-12-19 |
| CA2490888A1 (en) | 2004-01-08 |
| CA2490888C (en) | 2011-05-24 |
| US7449456B2 (en) | 2008-11-11 |
| US20090281072A1 (en) | 2009-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1518855A4 (de) | Diaminopyrimidincarbonsäureamidderivat | |
| UA94390C2 (ru) | Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких | |
| IS2520B (is) | Nikótínamíð afleiður nytsamlegar sem P38 hindrar | |
| EP1511730B8 (de) | Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen | |
| DE60332093D1 (de) | Neues phenylalaninderivat | |
| WO2004043367A3 (en) | Fused heterocyclic compounds and use thereof | |
| WO2004002981A3 (en) | Herbicidal thienylalkynes | |
| NO20064577L (no) | Tetrahydronaftyndin-derivater nyttige som histamin H3 reseptorligander | |
| ATE371656T1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| NO20041452L (no) | 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer. | |
| CY1108455T1 (el) | Νεος στεροειδης αγωνιστης δια fxr | |
| PE20060243A1 (es) | Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina | |
| MY140021A (en) | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors | |
| WO2003047520A3 (en) | SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS | |
| DK1578740T3 (da) | 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet | |
| BR0307071A (pt) | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico | |
| ATE355265T1 (de) | Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren | |
| NO20044442L (no) | Fosfatprodroger av fluoroksindoler | |
| WO2004043362A3 (en) | Acyl guanidine compounds and use thereof | |
| MXPA05009282A (es) | Derivados de anilina sustituidos. | |
| WO2004041802A8 (en) | 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders | |
| IS2473B (is) | Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess | |
| DK1441726T3 (da) | Derivater af phenoxy-N' -4-(isothiazolidin-1,1-dioxid-2-yl)phenyl]-valerianesyreamid og andre forbindelser som inhibitorer af koagulationsfaktoren Xa til behandling af thromboemboliske lidelser og tumorer | |
| WO2003063844A3 (en) | Treatment of rheumatoid arthritis using imatinie | |
| BRPI0314501B8 (pt) | processo para a preparação de um derivado de 2-aminometilpiridina e processo para a preparação de um derivado de cloridrato de éster de glicina piridina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |